CRISPR Therapeutics for Pancreatic Cancer
DOI:
https://doi.org/10.58445/rars.1031Keywords:
pancreatic cancer, CRISPR, Cancer TherapyAbstract
Pancreatic cancer is one of the most fatal cancers with a five-year survival rate of just 7.2%. The current treatments available for pancreatic cancer are often unsuccessful, creating a pressing need for more effective therapeutic options. CRISPR gene editing has emerged as a powerful tool with the potential to revolutionize cancer treatment strategies. Experiments using CRISPR in animal models have proven successful in stopping pancreatic cancer progression. This versatile technology can be used to edit, silence, or disrupt genes, presenting a novel avenue for treating genetic cases of pancreatic cancer in patients. In this review, I discuss the history behind CRISPR and its promising role in reshaping therapeutic approaches for pancreatic cancer.
References
American Cancer Society. 19 January 2024. Key Statistics for Pancreatic Cancer. Cancer.org.
Broad Institute. (n.d.). CRISPR Timeline. Broad Institute. https://www.broadinstitute.org/what-broad/areas-focus/project-spotlight/crispr-timeline
Christopher A. Lino, Jason C. Harper, James P. Carney & Jerilyn A. Timlin (2018) Delivering CRISPR: a review of the challenges and approaches, Drug Delivery, 25:1, 1234-1257, DOI: 10.1080/10717544.2018.1474964
Colombia Surgery. (n.d.). Pancreatic Cancer Prognosis. The Pancreas Center Columbia Surgery. https://columbiasurgery.org/pancreas/pancreatic-cancer-prognosis#:~:text=The%20overall%20five%2Dyear%20survival, the%20survival%20rate%20is%2010.7%25.
Committee on the Ethical and Social Policy Considerations of Novel Techniques for Prevention of Maternal Transmission of Mitochondrial DNA Diseases; Board on Health Sciences Policy; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine; Claiborne A, English R, Kahn J, editors. Mitochondrial Replacement Techniques: Ethical, Social, and Policy Considerations. Washington (DC): National Academies Press (US); 2016 Mar 17. Summary. Available from: https://www.ncbi.nlm.nih.gov/books/NBK355451/
Cribbs, A. P., & Perera, S. M. W. (2017). Science and Bioethics of CRISPR-Cas9 Gene Editing: An Analysis Towards Separating Facts and Fiction. The Yale journal of biology and medicine, 90(4), 625–634.
Dailey, K. M., Small, J. M., Pullan, J. E., Winfree, S., Vance, K. E., Orr, M., Mallik, S., Bayles, K. W., Hollingsworth, M. A., & Brooks, A. E. (2023). An intravenous pancreatic cancer therapeutic: Characterization of CRISPR/Cas9n-modified Clostridium novyi-Non Toxic. PloS one, 18(11), e0289183. https://doi.org/10.1371/journal.pone.0289183
Das, S. K., Menezes, M. E., Bhatia, S., Wang, X. Y., Emdad, L., Sarkar, D., & Fisher, P. B. (2015). Gene Therapies for Cancer: Strategies, Challenges and Successes. Journal of cellular physiology, 230(2), 259–271. https://doi.org/10.1002/jcp.24791
Gavin J. Knott, Jennifer A. Doudna, CRISPR-Cas guides the future of genetic engineering.Science, 361,866-869(2018).DOI:10.1126/science.aat5011
Guo, X. Z., Cui, Z. M., & Liu, X. (2013). Current developments, problems and solutions in the non-surgical treatment of pancreatic cancer. World journal of gastrointestinal oncology, 5(2), 20–28. https://doi.org/10.4251/wjgo.v5.i2.20
Guttinger, S. Trust in Science: CRISPR–Cas9 and the Ban on Human Germline Editing. Sci Eng Ethics 24, 1077–1096 (2018). https://doi.org/10.1007/s11948-017-9931-1
Javed, M.R., Sadaf, M., Ahmed, T. et al. CRISPR-Cas System: History and Prospects as a Genome Editing Tool in Microorganisms. Curr Microbiol 75, 1675–1683 (2018). https://doi.org/10.1007/s00284-018-1547-4
Jiang, W., Li, H., Liu, X., Zhang, J., Zhang, W., Li, T., Liu, L., & Yu, X. (2020). Precise and efficient silencing of mutant KrasG12D by CRISPR-CasRx controls pancreatic cancer progression. Theranostics, 10(25), 11507–11519. https://doi.org/10.7150/thno.46642
Jun Wan Shin, Kyung-Hee Kim, Michael J. Chao, Ranjit S. Atwal, Tammy Gillis, Marcy E. MacDonald, James F. Gusella, Jong-Min Lee, Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9, Human Molecular Genetics, Volume 25, Issue 20, 15 October 2016, Pages 4566–4576, https://doi.org/10.1093/hmg/ddw286
Li, M., Xie, H., Liu, Y., Xia, C., Cun, X., Long, Y., Chen, X., Deng, M., Guo, R., Zhang, Z., & He, Q. (2019). Knockdown of hypoxia-inducible factor-1 alpha by tumor targeted delivery of CRISPR/Cas9 system suppressed the metastasis of pancreatic cancer. Journal of controlled release: official journal of the Controlled Release Society, 304, 204–215. https://doi.org/10.1016/j.jconrel.2019.05.019
PDQ Adult Treatment Editorial Board. 28 February 2024. PDQ Pancreatic Cancer Treatment. National Cancer Institute. https://www.cancer.gov/types/pancreatic/patient/pancreatic-treatment-pdq.
Rose, Bruce I. MD, PhD; Brown, Samuel MD. Genetically Modified Babies and a First Application of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR-Cas9). Obstetrics & Gynecology 134(1):p 157-162, July 2019. | DOI: 10.1097/AOG.0000000000003327
Yang, H., Bailey, P., & Pilarsky, C. (2019). CRISPR Cas9 in Pancreatic Cancer Research. Frontiers in cell and developmental biology, 7, 239. https://doi.org/10.3389/fcell.2019.00239
Downloads
Posted
Categories
License
Copyright (c) 2024 Dylan Morris
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.